 

Active Ingredient: Abacavir sulfate; Dolutegravir sodium; Lamivudine 

 

Dosage Form; Route: Tablet; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in vivo 

Strength: 600 mg (Eq. abacavir base)/50 mg (Eq. dolutegravir base)/300 mg 
(lamivudine) 

Subjects: Normal healthy males and females, general population 

Additional comments: None 

______________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in vivo 

Strength: 600 mg (Eq. abacavir base)/50 mg (Eq. dolutegravir base)/300 mg 
(lamivudine) 

Subjects: Normal healthy males and females, general population 

Additional comments: None 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Abacavir, dolutegravir, and lamivudine 
in plasma 

 

Bioequivalence based on (90% CI): Abacavir, dolutegravir, and lamivudine 

 

Waiver request of in vivo testing: Not applicable 

 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the abbreviated new drug 
application (ANDA). 


